Cancer | 2023
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash M, Shah N, D'Souza A, Sidana S
PubMed
PMID: 37021929
Abstract
Related Articles
CIBMTR Study #: MM20-03